 Glucogon-like peptid-1, GLP-1, is an incretin hormone produced by intestinal L cells in response to nutrients. It plays a key role in regulating blood sugar levels by stimulating insulin production from pancreatic beta cells, slowing down digestion, reducing glucogon levels, and reducing appetite. GLP-1 based treatments are being used to manage type 2 diabetes due to their ability to lower blood sugar levels. Recently, researchers have discovered that these treatments can also reduce inflammation in various chronic inflammatory conditions, such as type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, non-alcoholic steetohepatis, diabetic nephropathy, asthma, and psoriasis. These treatments work by activating specific cellular pathways that reduce inflammation and promote healing. This article was authored by Youngson Lee and He Sik-Chun.